AmyK.KrieMD

Oncology • Minneapolis, MN

Breast Cancer, Hematologic Oncology

Assistant Professor, Internal Medicine, Sanford School of Medicine The University of South

Join to view full profile

Dr. Krie is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Krie's full profile

Already have an account?

Office
800 E 28th St
Ste 404
Minneapolis, MN 55407
Phone+1 612-863-0200

Fax+1 612-863-0235

Education & Training

Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2001 - 2004
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 2001

Certifications & Licensure

OR State Medical License 2003 - Present
MN State Medical License 2020 - 2025
IA State Medical License 2004 - 2022
SD State Medical License Active through 2021
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012
Most Compassionate Doctor American Registry

Clinical Trials

Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer Start of enrollment: 2006 Oct 12
Completed
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol Start of enrollment: 2014 Mar 01
Unknown status
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.
E Shelley Hwang, Terry Hyslop, Thomas Lynch, Marc D Ryser, Anna Weiss
JAMA. 2024-12-12
1 citations
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial.
Ann H Partridge, Terry Hyslop, Shoshana M Rosenberg, Antonia V Bennett, Sarah Drier
JAMA Oncology. 2024-12-12
Breast Cancer Polygenic Risk Score Validation and Effects of Variable Imputation.
Jeffrey J Beck, John L Slunecka, Brandon N Johnson, Austin J Van Asselt, Casey T Finnicum
Cancers. 2024-04-20